Chad Orevillo

723 total citations
20 papers, 335 citations indexed

About

Chad Orevillo is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Chad Orevillo has authored 20 papers receiving a total of 335 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 8 papers in Physiology and 2 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Chad Orevillo's work include Inhalation and Respiratory Drug Delivery (13 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (11 papers) and Asthma and respiratory diseases (8 papers). Chad Orevillo is often cited by papers focused on Inhalation and Respiratory Drug Delivery (13 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (11 papers) and Asthma and respiratory diseases (8 papers). Chad Orevillo collaborates with scholars based in United States, United Kingdom and Spain. Chad Orevillo's co-authors include Colin Reisner, Andrea Maes, Patrick Darken, Fernando J. Martínez, Gary T. Ferguson, Leonardo M. Fabbri, Shahid Siddiqui, Tracy Fischer, Ubaldo J. Martin and Michael A. Golden and has published in prestigious journals such as Neurology, CHEST Journal and Epilepsia.

In The Last Decade

Chad Orevillo

20 papers receiving 329 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chad Orevillo United States	9	320	263	12	6	5	20	335
Piet J.G. Cornelissen Netherlands	7	317 1.0×	281 1.1×	5 0.4×	1 0.2×		8	335
Leonard Dunn United States	6	181 0.6×	149 0.6×	2 0.2×			9	185
Tammy McIver United Kingdom	8	175 0.5×	180 0.7×	3 0.3×	1 0.2×		25	212
Anna-Carin Olin Sweden	5	62 0.2×	50 0.2×	18 1.5×	1 0.2×		6	103
Gulshan Malik United Kingdom	2	43 0.1×	47 0.2×	10 0.8×	2 0.3×	1 0.2×	5	86
Marc Csete United States	4	53 0.2×	54 0.2×	2 0.2×		2 0.4×	6	91
Julian Leggett United Kingdom	4	106 0.3×	63 0.2×		1 0.2×	7 1.4×	5	164
Faisal Fakih United States	4	46 0.1×	33 0.1×	4 0.3×	2 0.3×		5	71
David Cleveland United States	3	81 0.3×	51 0.2×	1 0.1×	5 0.8×		7	111
Julio Chertcoff Argentina	5	46 0.1×	33 0.1×	3 0.3×	2 0.3×	1 0.2×	18	69

Countries citing papers authored by Chad Orevillo

Since Specialization

Citations

This map shows the geographic impact of Chad Orevillo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chad Orevillo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chad Orevillo more than expected).

Fields of papers citing papers by Chad Orevillo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chad Orevillo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chad Orevillo. The network helps show where Chad Orevillo may publish in the future.

Co-authorship network of co-authors of Chad Orevillo

This figure shows the co-authorship network connecting the top 25 collaborators of Chad Orevillo. A scholar is included among the top collaborators of Chad Orevillo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chad Orevillo. Chad Orevillo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dlugos, Dennis, Ingrid E. Scheffer, Jacqueline A. French, et al.. (2025). Bexicaserin for the treatment of seizures in developmental and epileptic encephalopathies: A phase 1b/2a trial ( PACIFIC ). Epilepsia. 67(2). 646–659. 1 indexed citations

Parasrampuria, Dolly A., et al.. (2022). Single Ascending Dose Pharmacokinetics (PK), Pharmacodynamics (PD), and Tolerability of LP352 in Healthy Subjects (P14-8.001). Neurology. 98(18_supplement). 2 indexed citations

Parasrampuria, Dolly A., et al.. (2022). A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Pharmacokinetics (PK), Pharmacodynamics (PD), and Tolerability of LP352 in Healthy Subjects (P14-8.002). Neurology. 98(18_supplement). 1 indexed citations

Reisner, Colin, Leonardo M. Fabbri, Edward Kerwin, et al.. (2017). A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease. Respiratory Research. 18(1). 158–158. 21 indexed citations

Taylor, Glyn, Simon Warren, Sarvajna Dwivedi, et al.. (2017). Gamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technology. European Journal of Pharmaceutical Sciences. 111. 450–457. 37 indexed citations

Martínez, Fernando J., Leonardo M. Fabbri, Gary T. Ferguson, et al.. (2017). Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD. CHEST Journal. 152(6). 1169–1178. 37 indexed citations

Hanania, Nicola A., Donald P. Tashkin, Edward Kerwin, et al.. (2017). Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease. Respiratory Medicine. 126. 105–115. 57 indexed citations

Reisner, Colin, Gregory Gottschlich, Faisal Fakih, et al.. (2017). 24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPD. Respiratory Research. 18(1). 157–157. 15 indexed citations

Martínez, Fernando J., Klaus F. Rabe, Gary T. Ferguson, et al.. (2016). Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD. CHEST Journal. 151(2). 340–357. 94 indexed citations

10.

Fabbri, Leonardo M., Edward Kerwin, Selwyn Spangenthal, et al.. (2016). Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD. Respiratory Research. 17(1). 109–109. 14 indexed citations

11.

Tashkin, Donald P., Fernando J. Martínez, Roberto Rodríguez-Roisin, et al.. (2016). A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD. Respiratory Medicine. 120. 16–24. 20 indexed citations

12.

Sethi, Sanjay, Charles Fogarty, Nicola A. Hanania, et al.. (2016). Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension™ Delivery Technology Versus Foradil® Aerolizer® in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 4(1). 21–33. 6 indexed citations

13.

Taylor, Glyn, Simon Warren, Chad Orevillo, et al.. (2016). LATE-BREAKING ABSTRACT: Pulmonary deposition of a novel LAMA/LABA Co-Suspension^™technology glycopyrronium/formoterol (GFF) MDI in healthy subjects (PT003020). OA4834–OA4834. 2 indexed citations

14.

Fabbri, Leonardo M., Fernando J. Martínez, Klaus F. Rabe, et al.. (2016). Beneficial effect of the LAMA/LABA glycopyrronium (GP)/formoterol (FF) fixed-dose combination, delivered using a novel MDI co-suspension technology (GFF MDI), in COPD GOLD group A and B patients. PA310–PA310. 2 indexed citations

15.

Rabe, Klaus F., Fernando J. Martínez, Roberto Rodríguez-Roisin, et al.. (2015). LATE-BREAKING ABSTRACT: PT003, a novel co-suspension MDI glycopyrronium/formoterol fixed-dose combination is superior to monocomponents in patients with COPD. PA4363–PA4363. 6 indexed citations

16.

Reisner, Colin, et al.. (2012). Pearl Therapeutics’ Combination LAMA/LABA MDI (GFF MDI, PT003) Provides Comparable Metabolic And ECG Safety To Spiriva® Handihaler® And Placebo In Patients With COPD. A2925–A2925. 6 indexed citations

17.

Reisner, Colin, Stephen I. Rennard, Charles Fogarty, et al.. (2012). Pearl Therapeutics' Combination LAMA/LABA MDI (GFF-MDI, PT003) Provides A Significant Benefit On Home Peak Expiratory Flow Rate (PEFR) And Reduces The Need For Rescue Albuterol Use Compared To Its Components Administered Alone, Spiriva® Handihaler®, And Foradil® Aerolizer® In A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study In Patients With COPD. A2259–A2259. 11 indexed citations

18.

Lechuga‐Ballesteros, David, Reinhard Vehring, Michael A. Golden, et al.. (2012). Triple Drug Fixed Dose Combination Metered Dose Inhaler With Stable And Equivalent Drug Delivery Performance Relative To Individual And Dual Subcomponents. A3966–A3966. 1 indexed citations

19.

Lechuga‐Ballesteros, David, Michael A. Golden, Reinhard Vehring, et al.. (2012). Highly efficient dual and triple combination therapies with no coformulation effect for treatment of COPD. 40. 2152. 1 indexed citations

20.

Lechuga‐Ballesteros, David, et al.. (2012). Breaking microgram barrier to conduct dose ranging studies with long acting bronchodilators from a novel cosuspension metered dose inhaler product platform. 40. 2150. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact